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ABSTRACT 
Objective: Rheumatoid arthritis (RA) is a common disease affecting about 5 in 1,000 people in Malaysia. Medication adherence among RA patients 
can be as low as 30% and non-adherence of disease modifying anti-rheumatic drugs (DMARD) may result in irreversible joint damage. This study 
aimed to assess adherence rates and to identify potential factors influencing adherence.  
Methods: A cross-sectional study was conducted at Rheumatology Clinic of a tertiary hospital for 8 w from May to June 2014. A total of 51 RA 
patients using DMARD were recruited in this study. Researcher-assisted questionnaires were utilized. The study assessed adherence by using 
Compliance Questionnaire on Rheumatology (CQR5) and data retrieved from pharmacy dispensing records which were measured using Medication 
Possession Ratio (MPR). Questionnaires to assess beliefs about medicines and satisfaction about medicine information were also used. 
Subsequently, associations between adherence and demographics, socioeconomics, medication, disease and patient-related factors were 
determined.  
Results: The response rate was 75%. Depending on the instruments used, 75% (CQR5) and 60% (MPR) of the patients were adherent to DMARD. 
Non-adherence was not associated with demographic, socioeconomic and clinical characteristics, satisfaction about medication information and 
medication concerns. Beliefs about the necessity of medication (r = 0.372; p = 0.007) and necessity-concerns differential (r = 0.439; p = 0.001) were 
moderately associated with adherence.  
Conclusion: Patient-related factor was associated with medication adherence in our study population. The necessity-concerns differential of 
medication beliefs may serve as a possible screening tool for non-adherence or target for adherence-improving intervention among RA patients. 
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INTRODUCTION 
Adherence is defined as the extent to which a person’s behaviour 
corresponds with agreed recommendations from a healthcare 
provider [1]. Rheumatoid arthritis (RA) is a common disease with a 
prevalence of 0.5% to 1% of the adult population worldwide [2]. 
According to Arthritis Foundation Malaysia, it affects approximately 
5 in 1,000 people in this country. 
Disease-modifying anti-rheumatic drugs (DMARDs) will help in 
suppressing disease activity, improving functional ability, preventing 
irreversible joint damage and reducing the risk of extra-articular 
features such as cardiovascular disease [4]. Adherence to DMARD will 
determine the success of treatment. However, adherence is only 
suboptimal and ranges from ranged from 30% to 80%, depending on the 
definition of adherence and methodology of measurement used [5].  
It is a chronic inflammatory 
disease that is characterized by joint inflammation and is often 
associated with a poor quality of life [3]. It lays a huge financial 
burden with more than 50% of patients with RA completely stop 
working within 10 y of disease onset [3]. 
In order to improve adherence, non-adherent individuals have to be 
identified. The most feasible way to identify non-adherents in 
clinical practice is by using self-report measures because they are 
cheaper, minimal participant burden, ease and administrative speed, 
and flexibility in terms of mode of administration and timing of 
assessment compare to other measures [6]. There is no gold 
standard questionnaire for measuring patient adherence at present 
[7]. Compliance Questionnaire on Rheumatology (CQR) is the only 
validated rheumatology-specific adherence questionnaire [8]. 
However, self-report measures tend to overestimate adherence 
with socially desirable answers and are subjected to recall biases 
[6, 9]. Therefore, an objective measure such as refill of 
prescription can also be used to screen RA patients who are likely 
to be non-adherent [10]. 
Non-adherent behaviour can be associated with 5 interacting 
domains which are socioeconomic factors, health professional and 
health service-related factors, therapy-related factors, disease-
related factors and patient-related factors [11]. There is no single 
factor that can independently predict non-adherence inpatient [1]. 
Multiple risk factors from different dimensions need to be 
considered and investigated of their influence on RA patients [11]. 
Previous studies identified a variety of sociodemographic and 
clinical variables related to adherence, but none was consistently 
related in all studies, with sometimes contradictory [6, 11]. The aim 
of this study was therefore to assess patient’s adherence, medication 
beliefs and satisfaction with medication information of RA patient 
who was taking DMARD.  
MATERIALS AND METHODS  
Methods 
A cross-sectional survey was conducted at the Rheumatology Clinic 
of Universiti Kebangsaan Malaysia Medical Centre (UKMMC) over a 
period of 8 w. RA patients using DMARD were approached based on 
inclusion and exclusion criteria and researcher-assisted 
questionnaires were utilised. Convenience sampling was used. All 
questionnaires including the translated version were piloted on 10 
outpatients with RA and were subsequently modified to improve 
clarity before the actual data collection was started. Each interview 
started with an assessment of demographics and socioeconomics 
and clinical characteristics followed by completing three 
questionnaires: CQR, Satisfaction about Medication Scales (SIMS) 
and Beliefs about Medicines Questionnaire (BMQ). Ethical approval 
was obtained from the Research Ethic Committee of UKM (UKM 
1.5.3.5/244/NF-002-2014). Written consent was obtained from 
participants who agreed to participate and they were reassured of 
the confidentiality of the information provided. Participants in this 
study were strictly voluntary. 
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Patients were recruited if they were diagnosed with RA, aged 18 
y old and above and were taking at least one DMARD. Patients 
were excluded from the study if they were just recently started on 
DMARD (less than 1 y), were unable to give informed consent and 
unable to read or understand English, Malay or Mandarin, with 
documented cognitive impairment or psychiatric illness and were 
not responsible for their own medication taking (relied on a career). 
Targeted sample size was 140 subjects with 10 subjects per variable 
studied. The 14 factors to be assessed in our study were age, race, 
sex, employment status, education level, household income, marital 
status, duration of illness, pain intensity, the number of medicines 
prescribed, beliefs about medicines (2 subscales) and satisfaction 
with medication information (2 subscales). 
Data collection 
Instruments 
a) Beliefs about medicines questionnaire (BMQ)  
Patients’ beliefs about medicines were assessed using the BMQ. It 
has been validated for use in patients with various chronic illnesses 
[9]. Only part one BMQ was used and it consisted of two 5-item 
subscales. Item 1 to 5 was utilised to assess patients’ beliefs about 
the necessity of prescribed medication for controlling their disease 
while item 6 to 10 were utilised to assess their concerns about 
potential threats of taking it. Participants indicated their degree of 
agreement with each statement on a 5-point Likert scale, ranging 
from 1 = strongly disagree to 5 = strongly agree. The total scores 
were ranged from 5 to 25 for both necessity and concerns scales 
with higher scores indicating stronger beliefs. BMQ necessity–
concerns differential was calculated by subtracting the concerns 
subscale score from the necessity subscale score and the difference 
between the necessity and the concerns scales were ranged-20 
to+20. This differential could be thought of as the cost–benefit 
analysis for each patient, for whom costs (concerns) were weighed 
against their perceived benefits (necessity beliefs).  
b) Compliance questionnaire on rheumatology (CQR5) 
Adherence was assessed with CQR and computerized pharmacy 
refill records. The 5-item CQR (CQR5) was previously modified from 
the 19-item CQR, which was validated with Medication Event 
Monitoring System (MEMS device) in patients with inflammatory 
rheumatic diseases [8, 12]. CQR5 is a condensed questionnaire that 
would be quicker and easier to be utilised and able to reduce the patients’ 
burden but maintain a good level of reliability and validity. Each 5 item in 
CQR presents a statement, which is related to adherence rated on a 4-
point Likert scale ranging from 1 (do not agree at all) to 4 (agree very 
much). By using CQR5 Adherence Calculator, an estimation of whether 
the patient is a “high adherer” or a “low adherer” was calculated and the 
results were presented in dichotomous scale. 
c) Medication possession ratio (MPR)  
MPR of DMARD was calculated from automated pharmacy 
dispensing records as a proportion of day’s supply obtained over a 
period of refill intervals for the past one year. MPR was then 
calculated by a number of days for which DMARD(s) were dispensed 
between the start and the end date divided by the total number of 
days elapsed between the intervals. The obtained ratio was 
multiplied by 100%, and it was defined as poor adherence if refill 
adherence was less than 80% [13]. 
d) Satisfaction with information about medicines scale (SIMS)  
SIMS consists of 17 items to assess the extent to which patients feel 
they have received enough information about different aspects of 
their prescribed medicines from health care provider [14]. For each 
item, participants were asked to indicate whether the amount of 
information they had received was “too much”, “about right”, “too 
little”, “none received”, or “none needed”. The SIMS items are 
divided into two subscales: the action and use (Item 1-9) and the 
potential problems of medication (Item 10-17). Total satisfaction 
score can be obtained from each subscale by summing the scores for 
each item with higher scores indicating a higher degree of overall 
satisfaction with the amount of medication information received. A 
score of 1 if satisfied (“about right” or “none needed”) and score 0 if 
dissatisfied (“too much”, “too little”, or “none received”).  
Statistical analysis 
Descriptive data were presented in mean (±SD) or median (25th-75th 
percentile) depending on the parametric distribution of measured 
variables. Data transformations were performed if possible. 
Comparisons between risk factors of adherent and non-adherent 
patients were done using Mann-Whitney U test, Chi-square test and 
Independent-samples t-test depending on the scale and normality of 
tested variables. All statistical tests were two-tailed and p-value<0.05 
was considered statistically significant. The relationship between 
variables and adherence were tested using Spearman or Pearson 
correlation. All variables with p-value<0.10 in the bivariate analysis 
were entered in the multivariate analysis performed by the binary 
logistic regression. Data were analyzed using SPSS version 21. 
RESULTS 
A response rate of 75.0% was reported among RA patients who have 
fulfilled inclusion criteria. Race and gender were not further 
analyzed for their association with adherence due to insufficient 
sample or did not meet the assumption of most statistical tests. Only 
4 male patients were recruited in our study. Subject’s characteristics 
are described in table 1. 
The majority of the participants (51%) used single traditional 
DMARD, 45% used traditional combination DMARDs and 4% used 
biological DMARD. Most patients used methotrexate (70.7%), 
sulfasalazine (35.4%), leflunomide (33.5%) and hydroxychloroquine 
(9.8%) as DMARD. The majority of participants were women 
(92.2%). A total of 70.6% of patients were younger than 65 y old. 
The majority of patients were retired (49%). Meanwhile, 15.7% of 
participants had a monthly household income of less than RM 1000 
with most of them depended mainly on their pensions. 82.4% of 
participants were married and not staying alone. Participants have 
large pill burden with a median of 8 medications per day and long 
disease duration with 13.7 mean years. 
Based on CQR5, 74.5% of the patients were adherent with 
prescribed medicines. Using MPR, 60.8% of the patients were rated 
as adherent. CQR5 and MPR were found to have a moderate 
association with each other (Spearman’s rho  
In our study, the majority of the participants (69.0%) believed in the 
necessity of their arthritis medication to maintain their health (table 
4). Almost 85% of patients believed medications were able to 
protect them from becoming worse. Although there was no 
association between adherence and medication concerns, however, 
overall 55.7% reported concerns about potential adverse 
consequences of taking their medication. Nearly 75% of participants 
expressed their concern about potential long-term adverse effects 
and becoming too dependent on their medications. There was much 
less concern about inconveniences and disruption to life’s routines 
associated with taking arthritis medications 
= 0.315, p = 0.025). In 
other words, people who collected medication on time tending to 
report more adherence to medications. 
A number of variables were tested for possible associations with 
adherence, measured with the CQR5 (table 2). 
Adherence between employment and marital status, age, the 
number of medications prescribed, pain intensity, disease duration, 
medication concerns score and satisfaction with information about 
medications were found to be non-significant. There was no 
association between adherence with monthly household income 
(Spearman’s rho = 0.127, p = 0.375) and education level (Spearman’s 
rho = 0.037, p = 0.798). Only beliefs about the necessity of the 
medication (t = 2.169, p = 0.047) and necessity–concerns differential 
(t = 3.420; p = 0.001) were found to be significantly higher for the 
adherent group in our study. Both showed significant moderate 
association with adherence. Necessity–concerns differential has a 
higher positive correlation with adherence (r = 0.439; p = 0.001) 
than BMQ necessity score (r = 0.372, p = 0.007). However, only 
necessity-concerns differential seemed to be powerful enough to 
predict low adherence in our study (table 3). 
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Table 1: Demographic, socioeconomic, clinical and patient characteristics (n = 51) 
Characteristic Finding 
Age in years, mean (±SD) 58.6 (±10.8) 
Gender, n (%)  
Male  4 (7.8)  
Female 47 (92.2) 
Race, n (%)  
Malay 25 (49.0) 
Chinese 15 (29.4) 
Indian 6 (11.8) 
Others 5 (9.8) 
Education level, n (%)  
Never 2 (3.9) 
Primary 11 (21.6) 
Secondary 31 (60.8) 
University/College 6 (11.8) 
Postgraduate 1 (2.0) 
Employment status, n (%)  
Working at present 14 (27.5) 
Retired 25 (49.0) 
Never worked  9 (17.6) 
Unemployed due to disease  2 (3.9) 
Unemployed due to other reasons  1 (2) 
Marital status, n (%)  
Married/living together 42 (82.4) 
Married/living alone 2 (3.9) 
Single/living together  2 (3.9) 
Single/living alone 5 (9.8) 
Monthly household income, n (%)  
RM 1000 and below 8 (15.7) 
RM 1001-RM2000 21 (41.2) 
RM 2001-RM3000 11 (21.6) 
Above RM 3000 11 (21.6) 
Years of disease duration, mean (±SD) 13.7 (±9.2) 
Pain VAS, mean (±SD) 4.2 (±2.5) 
No. of medicines, median (IQR)  8 (5-11) 
BMQ necessity score, mean (±SD) 17.8 (±3.1) 
BMQ concerns score, mean (±SD) 16.1 (±3.4) 
BMQ necessity–concerns differential, mean (±SD) 1.7 (±4.4) 
SIMS action score, mean (±SD)  6.4 (±1.8) 
SIMS adverse effects score, median (IQR) 2.0 (1.0-4.0) 
BMQ: Beliefs about Medicines Questionnaire; SIMS: Satisfaction about Medication Scales; VAS: Visual Analog Scale 
 
Table 2: Comparison between sociodemographic, disease, therapy and patient-related factors of adherent and non-adherent patients (n = 51) 






Sociodemographic factors     
Age in years, mean (±SD) 59.5 (±9.9) 55.9 (±13.3) t = 1.024 0.311 




5 (38.5)8 (61.5) Yates' χ2 0.502 = 0.450 
Marital status, n (%)Married Single  32 (84.2)6 
(15.8) 
12 (92.3)1 (7.7) Yates' χ2 0.791 = 0.070 
Disease-related factors     
Years of disease duration, mean (±SD) 14.5 (±9.4) 11.2 (±8.4) t = 1.147 0.257 
Pain VAS, mean (±SD) 4.3 (±2.5) 4.0 (±2.9) t = 0.336 0.738 
Therapy-related factor     
No. of medicines, median (IQR)  8 (5-12) 7 (5-9) Z =-0.695 0.487 
Patient-related factors     
BMQ necessity score, mean (±SD) 18.5 (±2.4) 15.8 (±4.1) t = 2.169 0.047* 
BMQ concerns score, mean (±SD) 15.7 (±3.2) 17.5 (±3.9) t =-1.634 0.109 
BMQ necessity–concerns differential, mean (±SD) 2.8 (±3.8) -1.6 (±4.6) t = 3.420 0.001* 
SIMS action score, mean (±SD)  6.2 (±1.8) 6.9 (±1.8) t =-1.161 0.251 
SIMS adverse effects score, median (IQR) 2.0 (1.0-5.0) 2.0 (2.0-3.5) Z =-0.574 0.566 
Z=Mann-Whitney U test; χ2
 
= Chi-square test; t= Independent-samples t-test; *p<0.05 denotes statistical significance. BMQ: Beliefs about Medicines 
Questionnaire; SIMS: Satisfaction about Medication Scales; VAS: Visual Analog Scale 
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Table 3: Logistic regression predicting likelihood of reporting non-adherence 
Characteristic Odds Ratio 95% CI for odds ratio p-value 
BMQ necessity score 1.095 0.838-1.431 0.505 
BMQ necessity–concerns differential 1.267 1.108-1.508 0.048* 
*p<0.05 denotes statistical significance. BMQ: Beliefs about Medicines Questionnaire  
 
Table 4: Percentage of participant agreeing or strongly agreeing with Beliefs about Medicines Questionnaire (BMQ) statements (n = 51) 
BMQ statements % agreeing or strongly agreeing 
Necessity Scale  
My health, at present, depends on my medicines  76.5 
My life would be impossible without my medicines  58.8 
Without my medicines I would become very ill  60.8 
My health in the future will depend on my medicines  64.7 
My medicines protect me from becoming worse  84.3 
Concern Scale  
Having to take medicines worries me  56.9 
I sometimes worry about the long-term effects of my medicines  74.5 
My medicines are a mystery to me  39.2 
My medicines disrupt my life  33.3 
I sometimes worry about becoming too dependent on my medicines  74.5 
 
On the other hand, patient satisfaction was highest regarding 
information on how to obtain follow-up prescriptions and on how to 
use the medication (>90% satisfied patients) (table 5). Patients were 
least satisfied (<70% satisfied patients) with information provided 
for the majority of the items regarding potential problems of 
medication. Only non-Muslims were assessed for information 
regarding alcohol use. A total of 13.7% of patients were dissatisfied 
about information received regarding the potential risk 
of 
  
teratogenicity of arthritis medications, and two of them were in 
their childbearing age. 
Table 5: Satisfaction about medicine information in both adherent and non-adherent patients 
Effects and usage n % satisfied Potential problems n % satisfied 
Medicine name 51 80.4 Any side effects 51 41.2 
Indication 51 84.3 Side effect risk 51 37.3 
Effects  51 80.4 What to do when side effects occur 51 29.4 
Mechanism  51 74.5 Drug interactions 51 9.8 
Onset of action 51 31.4 Alcohol use 26 37.3 
Perceived effects 51 43.1 Drowsiness 51 19.6 
Duration medicine use 51 35.3 Effects on the unborn child 51 86.3 
Instruction of use 51 96.1 Missed doses 51 27.5 
Follow-up prescriptions 51 98    
 
DISCUSSION 
RA has been consistently found to be three times more common in 
women than men [15] but the ratio of male to female RA patients 
presented to our Rheumatology Clinic was approximately one-sixth, 
and this has not yet included male patients that did not fulfill 
inclusion criteria or unwilling to take part in the study.  
The adherence rate of 60% to 75% to DMARD in this study is in 
agreement with the previous study.6
Non-adherence of DMARD is hard to be identified using general 
characteristics [1, 6, 11, 16, 17]as results from our study suggested 
that only beliefs about necessity of medications and perceived 
necessity greater than medication concerns were associated with 
adherence and these was consistent with previous studies that they 
seem to convince patients of the need for medications [6, 16-18]. 
Patients’ motivation to commence and to continue with medication 
is influenced by the way in which they evaluate their need for 
treatment [9, 18]. Adherent patients had greater necessity-concerns 
differential. They seemed to engage in an implicit cost-benefit 
analysis that balanced their concerns about the potential threats 
against perceptions of the necessity of arthritis medication [9, 18].  
 Lower adherence rate was 
reported with MPR compared to CQR in our study. Possible 
explanations are the input of data into pharmacy administrative 
database may not be comprehensive especially during busy hours 
and for prescriptions that were amended manually, manual 
prescriptions would have been used, and medications would had 
been dispensed bypassing computerized pharmacy dispensing 
records. Therefore, MPR may underestimate adherence in our study. 
This explained moderate rather than strong association between 
MPR and CQR. Besides, possessions did not guarantee that 
medications were taken by patients using MPR measure. Despite 
limitation with MPR, it was still being used as an additional 
adherence tool to reduce the effect of bias with self-reported 
questionnaire alone. 
The cost-benefit analysis was powerful enough as predictor and 
screening tool for non-adherence in our study and was consistent 
with previous finding [9, 18]. Therefore, it served as a possible 
target for adherence-improving interventions. Despite strong beliefs 
about the necessity of their medication to decrease the symptoms of 
pain and fatigue, prevention of functional loss and cure of the 
disease, more than half of the RA patients in this sample reported 
strong concerns about potential adverse effects, particularly in the 
long term and becoming too dependent which were also consistent 
with previous findings [6, 18].  
Adherence-improving interventions were reported not very 
successful in RA patients [19]. Our findings suggested that 
effective intervention should be tailored to overcome the 
perceptual barrier such as fear of possible adverse effects and fear 
of dependence, increase the understanding and reason why 
medication is needed as for this group of patients with the aim of 
increase the perceived benefit of treatment and reduce perceived 
threats at the same time [1].  
Wee et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 7, 317-321 
321 
Not all items in SIMS were used; item “whether the medication will 
affect your sex life” was replaced with “effects on the unborn child” 
[6] because asking the irrelevant question can increase the concerns 
and thereby influencing adherence [20]. RA impacts on the sexual 
lives by limitations on sexual intercourse because of fatigue and pain 
with the disease itself [21] rather than arthritis medication. 
Although not related to adherence, there were around two-third of 
patients dissatisfied with the information provided regarding 
potential problem of arthritis medications. This needs to be 
highlighted as side effects of DMARDS can be detrimental e. g. 
serious hepatotoxicity, bone marrow suppression and pulmonary 
complications [22]. Furthermore, the risk of liver damage increases 
with alcohol consumption but two-third of non-Muslims patients 
were not informed regarding alcohol use [23]and the majority of 
them were put on methotrexate and leflunomide. The majority of 
samples were on leflunomide and methotrexate, but not all the 
childbearing age women were informed regarding the increased risk 
of foetal death and teratogenicity risk of their arthritis 
medications. 
1. World Health Organization. Adherence to long-term therapies: 
evidence for action. Geneva, Switzerland; 2003. 
Therefore, providing sufficient information is 
important because it will help in prompt discontinuation and seek 
for early treatment in patients experiencing side effects.  
Our study has highlighted several findings; however, it has several 
limitations. Limited sample size may lead to insufficient power and 
results in non-significant findings. A study from single centred 
Rheumatology Clinic would limit the generalization of the findings 
and caution must be exercised before applying to other settings. In 
addition, there may be a possible overestimation of adherence with 
self-report adherence due to Hawthorne effect [6] and the self-
reported measure was subjected to recall biases [9]. Furthermore, 
adherence is a dynamic process and patients’ beliefs can change over 
time. A longitudinal study with a larger sample are required as the 
cross-sectional study did not measure changes over time [6]. 
In conclusion, our findings demonstrated that a significant 
proportion of RA patients did not adhere to their DMARD 
prescription. Interventions and the educational programme should 
incorporate personal beliefs about medication and by improving 
adherence to DMARD will subsequently improve the efficacy of 
medical treatments. Although not related to adherence, our study 
suggested that patients require more information regarding their 
arthritis medication than what they currently received to facilitate 
the appropriate medication use. Similar to medication concerns, this 
should also be addressed during drug counseling.  
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